Pular para o conteúdo principal
Ranking Invest

FLGT - Fulgent Genetics, Inc.

Segmento: HealthcareFulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Análise Ranking Invest

Valuation estimado
$ 692.06 Mi
Valor de Mercado
$ 562.69 Mi
Desconto (AV)-18.7%
IVR
1.23A companhia vale 1,23 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.56O valuation alternativo equivale a -56% do valor de mercado da companhia.
MLL
-0.56O lucro líquido dos controladores em 16 trimestres equivale a -56% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 1.01 Bi

Dívida Líquida

-$ 26.30 Mi

L4T

-$ 84.38 Mi

MM4T

-26.36%

Indicadores Básicos

ROE

-8.38%

Índices de Previsibilidade

Receita Líquida

D0.10

Lucro

C0.43

Margem

C0.42

Índices de Tendência

Receita Líquida

D0.85

Lucro

F-6.29

Margem

F-4.73

Índices de Endividamento

DIV/PAT

-0.03

DIV/L4T

0.31

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.